Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 37

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 37
---
 NEOs upon the exercise of the options or any sale of the underlying shares of common stock. For the year ended December 31, 2024, Dr. Gottesdiener and Dr. Reine were granted time-based and performance-based stock options. The grant date fair value of the time-based stock options were $590,830 for Dr. Gottesdiener and $2,910,420 for Dr. Reine. The grant date fair values of the performance-based stock options based on probable outcome of the applicable performance metrics were $574,200 and $789,355 for Dr. Gottesdiener and Dr. Reine, respectively, and the grant date fair values of such performance-based options, based on maximum level of achievement of the applicable performance metrics, are $2,296,800 and $1,127,650 for Dr. Gottesdiener and Dr. Reine, respectively. Dr. Duffield was granted only time-based stock options during the year ended December 31, 2024.

(2) The amounts reflect the annual cash incentive compensation earned by our NEOs based on our achievement of certain corporate performance goals.

(3) All other compensation for Dr. Gottesdiener consists of (i) $19,666 in reimbursements for commuting expenses and $4,278 for related tax gross-up, and (ii) $8,841 for matching contributions under our 401(k) plan.

(4) Dr. Reine joined as our CFO in January 2024 and his 2024 base salary was pro-rated accordingly. Dr. Reine’s annual cash incentive compensation for 2024 was not pro-rated. Dr. Reine was not an NEO in 2023.

<div align='center'>24</div>

(5) Bonus for Dr. Reine represents a one-time sign-on bonus paid in connection with Dr. Reine’s commencement of employment with us as Chief Financial Officer.

(6) All other compensation for Dr. Reine consists of (i) $23,000 in reimbursements for housing expenses and $14,029 for related tax gross-up, (ii) $18,829 in reimbursement for commuting expenses and $5,805 related tax gross-up, and (iii) $6,875 for matching contributions under our 401(k) plan.

(7) Non-equity incentive plan compensation for Dr. Duffield consists of (i) the annual cash incentive compensation earned by Dr. Duffield in the amount of $